Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany - A registry-based/multicentric cohort study

被引:10
作者
Frahm, Niklas [1 ]
Ellenberger, David [1 ]
Fneish, Firas [1 ]
Christoph, Kleinschnitz [2 ,3 ]
Warnke, Clemens [4 ]
Zettl, Uwe K. [5 ]
Friedemann, Friedemann [6 ,7 ,8 ]
Rauser, Benedict [9 ]
Stahmann, Alexander [1 ]
Vogelmann, Vroni [9 ]
Flachenecker, Peter [10 ]
机构
[1] MS Forschungs & Projektentwicklungs gGmbH, MS Res & Project Dev gGmbH MSFP, Hannover, Germany
[2] Univ Hosp Essen, Dept Neurol, Essen, Germany
[3] Univ Hosp Essen, Ctr Translat & Behav Neurosci CTNBS, Essen, Germany
[4] Univ Hosp Cologne, Fac Med, Dept Neurol, Cologne, Germany
[5] Univ Rostock, Neuroimmunol Sect, Dept Neurol, Rostock, Germany
[6] Max Delbrueck Ctr Mol Med, Expt & Clin Res Ctr, Berlin, Germany
[7] Max Delbrueck Ctr Mol Med, NeuroCure Clin Res Ctr, Berlin, Germany
[8] Charite Univ Med Berlin, Berlin, Germany
[9] Novartis Pharma GmbH, Nurnberg, Germany
[10] Neurol Rehabil Ctr Quellenhof, Bad Wildbad, Germany
关键词
Multiple sclerosis; Secondary progressive; Disease course; Care; Disease activity; Classification; MAGNIMS CONSENSUS GUIDELINES; MRI;
D O I
10.1016/j.msard.2021.103281
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The tailored immunomodulatory treatment strategy for secondary progressive multiple sclerosis (SPMS) depends on disease activity. Objective: To assess the real-world situation in monitoring disease activity in SPMS patients and to identify associations of resulting subgroups with demographics, symptomatology, and therapy Methods: This study included 4,263 SPMS patients from the German MS register (GMSR). For the classification into 'active' and 'inactive' according to relapse activity and MRI findings during the year prior to the latest clinical visit, we used the following definitions: active - gadolinium enhancing (Gd+)/new T2 lesions or >= 1 relapse, inactive - neither Gd+/new T2 lesions nor relapses. The active, inactive, and unclassifiable patients were compared in terms of clinical data, socio-demographics, symptomatology, healthcare, and DMT. Results: Classification was possible for 1,513 (35.5%) SPMS patients, with 467 classified as active and 1,046 as inactive. For the classification, MRI data was available for 33.2% of the 4,263 patients. Higher MRI frequencies were observed for younger patients (OR 1.22 [1.12,1.33] per 10 years) with short disease duration (OR 1.19 [1.09, 1.30] per 10 years) (p < 0.001). Conclusion: MRI coverage was low, especially in elderly SPMS patients. Roughly one third of the SPMS patients presented markers of disease activity in the last year. Overall, the clinical differences (concerning symptomatology and care) between patients with active and inactive SPMS were small.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis
    Jiang, Xiaotong
    Shen, Changyu
    Caba, Bastien
    Arnold, Douglas L.
    Elliott, Colm
    Zhu, Bing
    Fisher, Elizabeth
    Belachew, Shibeshih
    Gafson, Arie R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 77
  • [32] Differentiation of relapsing-remitting and secondary progressive multiple sclerosis: a magnetic resonance spectroscopy study based on machine learning
    Eksi, Ziya
    Cakiroglu, Murat
    Oz, Cemil
    Aralasmak, Ayse
    Karadeli, Hasan Huseyin
    Ozcan, Muhammed Emin
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2020, 78 (12) : 789 - 796
  • [33] Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis
    Sabina Luchetti
    Nina L. Fransen
    Corbert G. van Eden
    Valeria Ramaglia
    Matthew Mason
    Inge Huitinga
    Acta Neuropathologica, 2018, 135 : 511 - 528
  • [34] Disease Activity and Progression of Disability in Multiple Sclerosis Patients Aged Over 50 With or Without Disease-Modifying Drug Treatment: A Retrospective Cohort Study
    Kondo, Akihiro
    Ikeguchi, Ryotaro
    Kitagawa, Kazuo
    Shimizu, Yuko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [35] Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA)
    Chisari, Clara Grazia
    Amato, Maria Pia
    Di Sapio, Alessia
    Foschi, Matteo
    Iaffaldano, Pietro
    Inglese, Matilde
    Fermo, Salvatore Lo
    Lugaresi, Alessandra
    Lus, Giacomo
    Mascoli, Nerina
    Montepietra, Sara
    Pesci, Ilaria
    Quatrale, Rocco
    Salemi, Giuseppe
    Clerici, Valentina Torri
    Totaro, Rocco
    Valentino, Paola
    Filippi, Massimo
    Patti, Francesco
    JOURNAL OF NEUROLOGY, 2024, 271 (10) : 6801 - 6810
  • [36] Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
    Vormfelde, Stefan Viktor
    Ortler, Sonja
    Ziemssen, Tjalf
    JMIR RESEARCH PROTOCOLS, 2016, 5 (01):
  • [37] Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study
    Yaldizli, Ozguer
    Pardini, Matteo
    Sethi, Varun
    Muhlert, Nils
    Liu, Zheng
    Tozer, Daniel J.
    Samson, Rebecca S.
    Wheeler-Kingshott, Claudia A. M.
    Yousry, Tarek A.
    Miller, David H.
    Chard, Declan T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (02) : 150 - 159
  • [38] Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients
    Lasek-Bal, Anetta
    Bartoszek, Karina
    Steposz, Arkadiusz
    Puz, Przemyslaw
    Bal, Wieslaw
    Kazibutowska, Zofia
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2017, 127 (10) : 859 - 863
  • [39] Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting
    Ng, Huah Shin
    Zhu, Feng
    Kingwell, Elaine
    Zhao, Yinshan
    Yao, Shenzhen
    Ekuma, Okechukwu
    Svenson, Lawrence W.
    Evans, Charity
    Fisk, John D.
    Marrie, Ruth Ann
    Tremlett, Helen
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (01) : 131 - 140
  • [40] Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
    Simonsen, Cecilia Smith
    Flemmen, Heidi Oyen
    Broch, Line
    Brunborg, Cathrine
    Berg-Hansen, Pal
    Moen, Stine Marit
    Celius, Elisabeth Gulowsen
    FRONTIERS IN NEUROLOGY, 2021, 12